The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of intraperitoneal (IP) administration of catumaxomab (C) as consolidation therapy for patients (pts) with relapsed epithelial ovarian cancer (OC) in second or third complete remission: GEICO 1001 study.
Ignacio Romero
No relevant relationships to disclose
Ana Oaknin
No relevant relationships to disclose
Jose Angel Arranz
No relevant relationships to disclose
Elena García-Martínez
No relevant relationships to disclose
Ana Herrero
No relevant relationships to disclose
Antonio Casado
No relevant relationships to disclose
Ana De Juan
No relevant relationships to disclose
Eva Guerra
No relevant relationships to disclose
Susana Hernando Polo
No relevant relationships to disclose
Ana Santaballa
No relevant relationships to disclose
Andres Poveda
No relevant relationships to disclose
Antonio Gonzalez-Martin
No relevant relationships to disclose